Orchid Pharma gets EIR from USFDA for its Alathur facility
New Delhi: Orchid Pharma on Thursday said it has received establishment inspection report (EIR) from the US health regulator for its Alathur facility in Tamil Nadu.
The company has received EIR from the United States Food and Drug Administration (USFDA) based on the successful inspection of the active pharmaceutical ingredients (API) manufacturing facility at Alathur, Orchid Pharma said in a filing to BSE.
The facility was inspected by the USFDA on May 2017, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd